Freeline Therapeutics Holdings plc Quarterly Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect in USD from Q1 2020 to Q1 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Summary
Freeline Therapeutics Holdings plc quarterly/annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect history and growth rate from Q1 2020 to Q1 2023.
  • Freeline Therapeutics Holdings plc Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for the quarter ending March 31, 2023 was $6.51M.
  • Freeline Therapeutics Holdings plc annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2022 was -$70.5M, a 37.4% increase from 2021.
  • Freeline Therapeutics Holdings plc annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2021 was -$113M, a 172% decline from 2020.
  • Freeline Therapeutics Holdings plc annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2020 was $157M, a 170% increase from 2019.
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Quarterly (USD)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2023 $6.51M +$11.1M Jan 1, 2023 Mar 31, 2023 6-K 2023-05-30
Q1 2022 -$4.58M +$29.8M +86.7% Jan 1, 2022 Mar 31, 2022 6-K 2023-05-30
Q1 2021 -$34.4M -$13.1M -61.4% Jan 1, 2021 Mar 31, 2021 6-K 2022-05-10
Q1 2020 -$21.3M Jan 1, 2020 Mar 31, 2020 6-K 2021-05-17
* An asterisk sign (*) next to the value indicates that the value is likely invalid.